July 16, 2025 · Form 4 insider transaction
Krishnan Suma sold 1,389 shares of Krystal Biotech, Inc. at $150.00 per share, a transaction worth $208.3K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 0 days after the transaction.
The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.; The transaction was executed in one trade.; Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.